MedTrace Logo

Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

NCT05790941 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-03-30

No results posted yet for this study

Summary

Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.

Conditions

  • Hypotrichosis

Interventions

COMBINATION_PRODUCT

Latanoprost and Minoxidil

Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.

Sponsors & Collaborators

  • Aneira Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Dan Cosgrove, M.D. · WellMax

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-11
Primary Completion
2023-06-30
Completion
2023-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05790941 on ClinicalTrials.gov